The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic
Abstract
The beneficial actions of nonsteroidal anti‐inflammatory drugs (NSAIDs) have been linked to their ability to inhibit inducible COX‐2 at sites of inflammation, and their side effects (e.g., gastric damage) to inhibition of constitutive COX‐1. Selective inhibitors of COX‐2, such as celecoxib, etoricoxib, lumiracoxib, rofecoxib, and valdecoxib have been developed and the greatest recent growth in our knowledge in this area has been come from the clinical use of these compounds. Although clinical data indicate that COX‐2 selectivity is associated with a reduction in severe gastrointestinal events, they also reveal there are roles for constitutive COX‐2 within tissues such as the brain, kidney, pancreas, intestine, and blood vessels. We now better understand the roles of COX‐1 and COX‐2 in functions as disparate as the perception of pain and the progression of cancers. Clinical use of COX‐2‐selective compounds has ignited strong debates regarding potential side effects, most notably those within the cardiovascular system such as myocardial infarctions, strokes, and elevation in blood pressure. This review will discuss how the latest studies help us understand the roles of COX‐1 and COX‐2 and what clinically proven benefits the newer generation of COX‐2‐selective inhibitors offer.—Warner, T. D., Mitchell, J. A. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 18, 790–804 (2004)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Subbaramaiah, K., Lin, D. T., Hart, J. C., & Dannenberg, A. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007237200 · Cited by 275
RetractedBombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., et al. (2000) · JAMA · doi:10.1001/jama.284.10.1247 · Cited by 3,154
Cyclooxygenases: Structural, cellular, and molecular biology
Smith, W. L., DeWitt, D. L., & Garavito, R. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.145 · Cited by 2,925
Vane, J. R., Bakhle, Y. S., & Botting, R. M. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.97 · Cited by 2,734
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526
Cyclooxygenase in biology and disease
DuBois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., van de Putte, L. B. A., & Lipsky, P. E. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.12.1063 · Cited by 2,506
Chandrasekharan, N. V., Dai, H., Roos, K. L. T., Evanson, N. K., Tomsik, J., Elton, T. S., & Simmons, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162468699 · Cited by 1,989
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
Cited by
Wyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., & Taubert, K. A. (2007) · Circulation · doi:10.1161/circulationaha.106.181424 · Cited by 804
Diclofenac: an update on its mechanism of action and safety profile
Gan, T. J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.486301 · Cited by 600
Cardiovascular effects and safety of (non-aspirin) NSAIDs
Schjerning, A.-M., McGettigan, P., & Gislason, G. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0366-z · Cited by 387
Metadata
- Authors
- Warner, T. D., & Mitchell, J. A.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2004-05
- Volume
- 18
- Issue
- 7
- Pages
- 790-804
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2076744535
- Cited by
- 614
- References
- 135
- FWCI
- 35.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. https://app.cochat.ai/papers/10.1096/fj.03-0645rev
- The paper
- Warner, T. D., & Mitchell, J. A. (2004). Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. The FASEB Journal. https://doi.org/10.1096/fj.03-0645rev
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
